Mometasone - Merck & Co
Alternative Names: Altosone; Asmanex Twisthaler; Ecotone; Ecural; Elica; Elocon; Fulmeta; Mometasone furoate monohydrate; Nasonex; Novasone; Rinelon; Rivelon; SCH 32088; UniclarLatest Information Update: 05 Nov 2023
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated hydrocarbons; Furans; Glucocorticoids; Phenanthrenes; Pregnadienediols; Skin disorder therapies; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Asthma; Nasal polyps; Perennial allergic rhinitis; Seasonal allergic rhinitis; Sinusitis; Skin disorders
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 10 May 2018 Kyorin Pharmaceutical acquires distribution rights from MSD for mometasone for Allergic rhinitis in Japan
- 28 Feb 2017 Merck has patent protection for mometasone (Asmanex®) in Europe and Japan (Merck Annual report 2016)
- 15 Sep 2016 MSD and Kyorin agree to co-promote Nasonex® in Allergic rhinitis in Japan